CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2021;19(4):448-460.   Published online August 18, 2020
DOI: https://doi.org/10.5217/ir.2020.00026

Excel Download

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Intestinal Research. 2021;19(4):448-460   Crossref logo
Link1 Link2 Link3

Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use
Drugs & Therapy Perspectives. 2021;37(12):563-572   Crossref logo
Link1 Link2 Link3

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(10):979-979   Crossref logo
Link1 Link2

Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
BioDrugs. 2014;29(1):57-67   Crossref logo
Link1 Link2 Link3

P427 Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
Journal of Crohn's and Colitis. 2021;15(Supplement_1):S431-S432   Crossref logo
Link1 Link2

Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in Russia
Value in Health. 2017;20(9):A635   Crossref logo
Link1 Link2

Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
BioDrugs. 2015;29(1):73-73   Crossref logo
Link1 Link2 Link3

631 A Multi-Center Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Patients With Moderately-Severely Active Ulcerative Colitis
Gastroenterology. 2016;150(4):S132   Crossref logo
Link1 Link2

Safety and Efficacy of a New 3.3g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Yearbook of Gastroenterology. 2009;2009:110-111   Crossref logo
Link1 Link2

Efficacy and Safety of Single Fecal Microbiota Transplantation for Japanese Patients with Mild to Moderately Active Ulcerative Colitis
Gastroenterology. 2017;152(5):S574   Crossref logo
Link1 Link2